SMART Concussion Trial: Symptom Management vs Alternative Randomized Treatment of Concussion Trial (SMART)

Symptom Management vs Alternative Randomized Treatment of Concussion Trial

Given the rising rates of concussion in youth ages 10-19 and the significant proportion of young people who remain symptomatic for months following concussion, research evaluating the efficacy of multifaceted treatment options following concussion is imperative. Studies examining the efficacy of treatment strategies following concussion in children and adults are surprisingly limited, and most focus on one treatment approach, have small sample sizes, are not randomized controlled trials, and focus on individuals with prolonged recovery (months). There is a need for a multifaceted treatment trial to examine the early implementation of treatment approaches that may reduce prolonged recovery while considering the heterogeneous presentation of symptoms and patient preferences in the sub-acute stage following concussion. Randomized controlled trials that consider a multifaceted transdisciplinary approach to treatment in the early period following concussion are needed to raise the bar regarding evidence-informed management following concussion

Study Overview

• Status: Recruiting
• Conditions: Neck Pain; Dizziness; Mild Traumatic Brain Injury; Headaches Posttraumatic
• Intervention / Treatment: Procedure: Symptom-specific Headache Treatment; Other: Symptom-specific Dizziness &/or Neck Pain Treatment; Behavioral: Multimodal Concussion Treatment

Detailed Description

The primary objective of this RCT is to examine if up to 6-weeks of symptom-specific (1. headache, 2. dizziness and/or neck pain) treatment initiated in the acute/sub-acute stages following concussion in 13-19 year-old participants recruited acutely (within 2 weeks) following concussion are superior to up to 6 weeks of a multimodal, non-symptom specific treatment program. Treatment will cease once participants are cleared to return to unrestricted physical activity by a sports medicine physician, and will therefore last up to 6 weeks. We have two primary outcomes:

1. Post-Concussion Total Symptom Score (PCSS /132) on the SCAT5 following treatment of up to six sessions
2. Days from injury to physician clearance to return to unrestricted physical activity (e.g., physical education, sport, recreational activities)

• Study Type: Interventional
• Enrollment (Estimated): 164
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Heather Godfrey, MNNP, BSc, BN; Phone Number: 4039552797; Email: heather.godfrey@ahs.ca
• Study Contact Backup: Name: Astrid Han, Bsc; Phone Number: 4036712852; Email: astrid.han@ucalgary.ca

Study Locations

• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N 1N4
      • Recruiting
      • University Of Calgary
      • Contact: Heather Godfrey, BSc, BN; Phone Number: 4039552797
      • Contact: Lisa Marie Langevin, PhD; Phone Number: 4039557254
      • Principal Investigator: Carolyn Emery, PhD
      • Principal Investigator: Keith Yeates, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 13 years to 19 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 13 - 19 years of age at the start of treatment
• Diagnosed by the study physician with a concussion as per the 5th International Consensus Statement on Concussion in Sport1
• Glasgow Coma Scale 13-15 if recorded
• Loss of consciousness < 30 minutes if present
• Post-traumatic amnesia < 24 hours if present
• Diagnosis within 2 weeks of injury
• Moderate-severe symptoms of dizziness, neck pain, headaches, or sleep disturbance at > one week and < three weeks post injury reported on the PCSS (3-6 on 0-6 Likert scale for at least one of three symptoms)
• Patients can have a history of migraine or a family history of migraine

Exclusion Criteria:

• Inability to communicate orally and/or in writing in English language
• Significant developmental delay or intellectual disability
• No access to smartphone or computer
• Red flags or other clinical indication suggesting that further medical investigation is warranted (e.g., neurological scan - reflexes, dermatomes, myotomes, long tract signs, CN II-XII, Cerebellar Scan
• Unresolved Benign Paroxysmal Positional Vertigo (BPPV) (Dix-Hallpike and Roll Test)
• Inability to participate in physical activity for a reason other than concussion
• Orthopedic or other injury precluding ability to participate
• Medical history of neurological conditions: seizures (febrile SZ will be allowed), stroke, previous moderate/severe TBI, CNS cancers, SCI
• Psychotic disorder
• Inability to provide informed consent
• History of surgery in the occipital region
• Uncontrolled rheumatologic, inflammatory, or neurologic disorders (eg MS); Fibromyalgia/chronic fatigue syndrome; coagulopathy; immunosuppression
• Active cancer
• Herpes zoster infection in last 6 months
• Pregnancy
• Steroid injection to the greater or lesser occipital nerve infiltration in past 3 months
• Previously enrolled in the trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Headache Treatment; Participants in the headache arm will be randomized to receive a peripheral, greater occipital nerve block with 0.5% Bupivacaine or the multimodal treatment protocol. Participants will complete a daily headache diary over the 6-week treatment period, following a link on their mobile device. Patients receiving a nerve block will have weekly over-the-phone or virtual check-ins by the study team to evaluate for any side effects, pain, as needed medications, and study compliance. These patients will be given supplemental HA education as needed. Participants receiving the block will be offered a second block at 6 weeks if they meet the following criteria: a. no side effects with the first block, b. participant received relief from the first block and prefers a second, and c. headache is still occurring at least once per week. Participants randomized to the multimodal treatment portion, will have up to 6 weeks of scheduled multimodal treatment sessions.	Procedure: Symptom-specific Headache Treatment; Greater Occipital Nerve Block; Behavioral: Multimodal Concussion Treatment; Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
Experimental: Dizziness and/or Neck Pain Treatment; Participants will be randomized to receive cervicovestibular physiotherapy (CV PT) or the multimodal treatment program. The CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings for six weeks. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, and dynamic balance.	Other: Symptom-specific Dizziness &/or Neck Pain Treatment; Cervicovestibular Physiotherapy Treatment; Behavioral: Multimodal Concussion Treatment; Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
Experimental: Multimodal Treatment; The multimodal treatment consists of 6 treatment sessions that will combine basic physiotherapy exercises to address dizziness and balance problems, training in deep breathing, progressive muscle relaxation, visualization to address headache, sleep hygiene education to address insomnia, and cognitive-behavioral intervention and gratitude exercises to promote coping and resilience. The treatment is designed to be implemented by a variety of clinical health care professionals.	Behavioral: Multimodal Concussion Treatment; Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in symptoms	Change from baseline in symptom burden, measured by the Post-Concussion Symptom Score (PCSS /132) on the SCAT5 (Sport Concussion Assessment Tool - 5th Edition) at 6 weeks following initiation of treatment. Options for scores are: none (0), mild (1), moderate (2), or severe (3) in 22 symptom categories, for a total score of 0 (no symptoms) to 132 (severe symptoms in all categories)	Collected at 6 weeks from the start of treatment
Return to unrestricted physical activity	Days from injury to physician clearance to return to unrestricted physical activity (e.g., physical education, sport, recreational activities)	Measured until 3 months from the start of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in symptoms on the Buffalo Concussion Treadmill Test	Change in overall symptoms [visual analogue scale (VAS) 0-10] from rest prior to the Buffalo Concussion Treadmill Test (BCTT) to age-predicted 80% maximum heart rate on the BCTT at 6-weeks. 0 indicates 'Feeling Good' up to 10 'Worst I have ever felt'.	Measured at 6 weeks from the start of treatment
Changes in symptom-specific ratings	Symptom-specific PCSS [Post-Concussion Symptom Score (PCSS /132)] ratings of headache, dizziness/neck pain, and sleep disturbance [0-6 Likert scale; from no symptoms (0), to moderate (3), to severe (6)]	Measured at 6 weeks from the start of treatment
Change in quality of life rating	Pediatric Quality of Life Inventory V4.0 (PedsQL) at 6-weeks. Likert scale: never a problem (0) to sometimes (2) to almost always (4). Total symptom scores from 0/94 up to 94/94. Higher scores indicate poorer quality of life	Measured at 6 weeks from the start of treatment
Change in resilience	Resilience at 6-weeks using the short, 10-item Connor-Davidson Resilience Scale (CD-RISC). Respondents rate items on a 5-point Likert scale, ranging from 0 (not true at all) to 4 (true nearly all the time) for a score range of 0-40. A higher score indicates higher resilience	Measured at 6 weeks from the start of treatment

Collaborators and Investigators

• Sponsor: University of Calgary
• Collaborators: Canadian Institutes of Health Research (CIHR)
• Investigators: Principal Investigator: Carolyn Emery, PhD, University Of Calgary

Study record dates

Study Major Dates

• Study Start (Actual): April 10, 2023
• Primary Completion (Estimated): April 30, 2025
• Study Completion (Estimated): April 30, 2025

Study Registration Dates

• First Submitted: June 7, 2022
• First Submitted That Met QC Criteria: July 5, 2022
• First Posted (Actual): July 6, 2022

Study Record Updates

• Last Update Posted (Actual): September 11, 2023
• Last Update Submitted That Met QC Criteria: September 6, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Wounds and Injuries; Craniocerebral Trauma; Trauma, Nervous System; Sensation Disorders; Headache Disorders; Head Injuries, Closed; Wounds, Nonpenetrating; Headache Disorders, Secondary; Brain Injuries; Brain Injuries, Traumatic; Neck Pain; Dizziness; Headache; Brain Concussion; Post-Traumatic Headache
• Other Study ID Numbers: REB21-1045

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No